New Study Strengthens Link between Prilosec, Prevacid, Nexium and other PPIs and Fractures
Research shows increase in bone fractures among RA patients.
Monday, September 14, 2020 - 
United Kingdom researchers discovered a significant link between osteoporotic bone fractures in patients with rheumatoid arthritis and use of a combination of glucocorticoids (GCs) and proton pump inhibitors (PPIs) like Prilosec, Prevacid, and Nexium. The findings are the latest in a growing pile of research connecting PPIs to fractures.
The results, presented at the annual American Society for Bone and Mineral Research meeting September 11 through 15, 2020, are the result of cohort studies that compiled records from 12,351 rheumatoid arthritis patients from 1997 through 2017. A cohort study takes a look at subjects with a common experience or trait (in this case, people using PPIs and GCs) and follows them through a given period of time to compare specific outcomes (in this case, bone fractures).
This latest study adds to several other peer-reviewed studies that indicate a link between PPIs and fractures. PPIs have also been linked to stomach and esophageal cancers.
In this most recent study, 69% of those studied were women, and their median age was 68 years old. A total of 1,411 fractures of the hip, humerus, vertebrae, pelvis, forearm, and ribs occurred among this group, and were more likely among those who used both GCs and PPIs (hazard ratio 1.60). Those who took one or the other and not both also showed an increased risk of fracture, though not as high an occurrence as those who used both (hazard ratios 1.23 for glucocorticoids alone and 1.22 for PPIs alone). In models adjusted for age and gender, PPI use was linked to a 1.3-fold increase in fractures.
At the virtual conference, researchers concluded, "Considering the increasing life expectancies and high consumption of PPIs among elderly patients, these findings may be clinically relevant in patients [with] RA treated with oral GCs in combination with PPIs."
If you have rheumatoid arthritis and suffered bone fractures after taking PPIs and/or glucocorticoids, contact OnderLaw at 314-963-9000. We take on corporations that put profits over people, and we hold drug companies accountable for putting consumers at risk without warning them about potential side effects.
Source: Abtahi S, Driessen JHM, Burden AM, et al. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures in patients with rheumatoid arthritis: a population-based cohort study. Presented at: ASBMR 2020 Virtual Annual Meeting; September 11-15, 2020. Poster #P-546.
Tags for This Article:
More Recent Lawsuit News:
- U.S. Residents Spend More than Twice as Much on Rx Drugs | 1/29/2021
- Soho Fresh Rubbing Alcohol Recalled for Methanol Contamination | 1/11/2021
- Penumbra Issues Urgent Recall of Stroke Catheter | 12/22/2020
- Zantac Makers Face DOJ Probe | 12/21/2020
- FDA Issues Warnings on Janumet and Januvia | 12/8/2020
No-Cost, No-Obligation Case Review.
OnderLaw, LLC in St. Louis has developed a solid reputation of excellence as a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. OnderLaw has represented clients throughout the United States in pharmaceutical and medical device litigation, including Pradaxa, Lexapro and Yasmin/Yaz, Actos, Risperdal and others. OnderLaw has won verdicts of more than $300 million in talcum powder ovarian cancer lawsuits and represent more Glyphosate victims than any other firm in the country.
